Dear Shareholders, Partners, and Visionaries,
I am thrilled to share a ground-breaking development from Ocumetics Technology Corp. that marks a monumental step forward in the world of vision enhancement. Today, I am pleased to announce the successful manufacture of our accommodating intraocular lens (IOL) designed to respond to the natural muscle activity of the human eye. This achievement is not just a milestone for Ocumetics but a transformative moment in the field of ophthalmology.
Our team at Ocumetics has been relentlessly dedicated to advancing vision technology. The newly fabricated intraocular lens is designed to respond dynamically to the ciliary muscles—the very muscles that control the natural lens of the eye – allowing it to change focus seamlessly from near to far, much like a healthy, youthful eye. This innovation is a game-changer for millions who rely on glasses or contact lenses for clear vision. It’s designed to replicate the accommodation ability of a 10-year-old, and offer unprecedented visual clarity across all distances.
The path to this breakthrough has been paved with extensive research, innovative thinking, and a commitment to excellence. I would like to take a moment to acknowledge the incredible work of Dr. Garth Webb, our Chief Scientist, who has devoted over a decade to the intricate design details of this lens. Today, his theoretical concepts have been validated through rigorous laboratory experiments, demonstrating the lens’s ability to change focus in response to physiologic compression forces—just as the natural lens does in a healthy human eye. This is an extraordinary confirmation that our vision for an accommodating IOL is not just viable but is on the verge of becoming a reality.
What makes this achievement particularly exciting is the real-world impact it promises. Our accommodating IOL has the potential to restore natural vision to millions of people, enhancing quality of life and reducing dependence on corrective eyewear. As we prepare for the first human implantation of this lens in early 2025, we are filled with anticipation and confidence in the revolutionary potential of our technology.
This is a significant leap forward, positioning Ocumetics at the forefront of accommodating lens design. Our goal is not just to compete in the ophthalmology market but to lead it with cutting-edge solutions that transform how we perceive vision care. Our accommodating IOL is just one example of how we are pushing the boundaries of what is possible in vision enhancement.
As we look ahead to the next steps, I want to extend my deepest gratitude to our team, partners, and investors. Your support has been instrumental in reaching this pivotal moment. Together, we are not just witnessing history; we are making it.
To everyone who has believed in our vision from the beginning, thank you. We are on the cusp of delivering a product that will redefine the standard of eye care worldwide. The future of vision correction is here, and it is brighter and clearer than ever before.
Stay tuned for more updates as we prepare for our next major milestone – the first human implantation of the Ocumetics accommodating IOL. Together, we are shaping the future of vision.
Best Regards,
Dean Burns
President & CEO
Ocumetics Technology Corp.
Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire – May 12, 2026
Calgary, Alberta – TheNewswire – April 29, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to
Key Highlights Vision performance: Clinical outcomes exceed expectations, with all patients experiencing continuing vision improvements Safety profile: Continues to meet expectations Quality-of-life improvements: Anecdotally, all patients reported life changing results from lens implantations Technology validation: Results reinforce the expected performance of Ocumetics’ inaugural accommodating intraocular lens Momentum: Forward momentum continues, with lens design enhancements
Key Highlights No material change: There is no material change in the business affairs of Ocumetics. Attendance at ASCRS: Productive ASCRS meetings with major global ophthalmic leaders. Clinical and development momentum: Feedback supported positive results from the First-in-Human (FIH) Group 1 study while the Company advances toward Group 2 patient recruitment and upcoming surgeries. Regulatory
